11 completed, 2 enrolling by invitation, 2 withdrawn, 1 active not recruiting. 7 Phase 2, 5 Phase 3, 5 Phase 4, 3 Phase 1, 1 Early Phase 1.
Follow tapinarof: new trials by email Literature Review of tapinarof trials Research Report on tapinarof
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream - Atopic Dermatitis | Phase 3 | Suspended | Organon and Co | 187 | 2025-12-29 | 2026-10-05 |
| A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 575 | 2025-10-13 | 2026-04-22 |
| Tapinarof for Cutaneous Lupus Erythematosus Tapinarof - Cutaneous Lupus Erythematosus | Early Phase 1 | Enrolling by invitation | Northwestern University | 10 | 2025-04-03 | 2026-04-29 |
| Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma Tapinarof - Palmoplantar Keratoderma | Phase 2 | Active not recruiting | Indiana University | 6 | 2024-10-30 | 2026-06-23 |
| Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) Betamethasone dipropionate 0.05%, Tapinarof - ICD10 Code L40.9 for Psoriasis | Phase 2 / Phase 3 | Enrolling by invitation | Wake Forest University Health Sciences | 40 | 2024-07-15 | 2026-08-04 |
| A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region VTAMA (tapinarof) cream, 1% - Psoriasis | Phase 4 | Completed | Organon and Co | 31 | 2023-03-13 | 2025-06-12 |
| Vtama in Psoriasis Patients Being Treated With Biologics. Tapinarof - Psoriasis | Phase 4 | Completed | Psoriasis Treatment Center of Central New Jersey | 30 | 2023-02-27 | 2023-10-27 |
| A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis VTAMA® (tapinarof) Cream 1% - Psoriasis | Phase 4 | Completed | Organon and Co | 34 | 2022-12-27 | 2025-06-12 |
| Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults Benvitimod - Psoriasis | Phase 4 | Unknown | Peking University People's Hospital | 2000 | 2021-06-01 | 2021-10-01 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Tapinarof, Vehicle Cream - Plaque Psoriasis | Phase 3 | Completed | Organon and Co | 515 | 2019-06-06 | 2025-06-12 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Tapinarof, Vehicle Cream - Plaque Psoriasis | Phase 3 | Completed | Organon and Co | 510 | 2019-05-21 | 2025-06-12 |
| GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis GSK2894512 1% cream, Vehicle cream - Psoriasis | Phase 3 | Withdrawn | GlaxoSmithKline | 2018-01-22 | 2017-12-07 | |
| A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects GSK2894512 1% CREAM, GSK2894512 MATCHING VEHICLE CREAM - Psoriasis | Phase 1 | Withdrawn | GlaxoSmithKline | 2017-12-14 | 2017-11-29 | |
| A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream - Dermatitis, Atopic | Phase 2 | Completed | GlaxoSmithKline | 247 | 2015-12-01 | 2017-11-20 |
| A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream - Psoriasis | Phase 2 | Completed | GlaxoSmithKline | 227 | 2015-11-23 | 2017-11-13 |
| A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks WBI-1001 - Psoriasis | Phase 2 | Completed | Welichem Biotech Inc. | 61 | 2010-01-01 | 2012-12-20 |
| Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream WBI-1001 - Dermatitis, Atopic | Phase 2 | Completed | Welichem Biotech Inc. | 148 | 2009-11-01 | 2011-06-13 |
| Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis WBI-1001 - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Welichem Biotech Inc. | 36 | 2008-03-01 | 2009-02-05 |
Psoriasis (11) · Dermatitis, Atopic (5) · Eczema (2) · Skin Diseases (2) · Keratoderma, Palmoplantar (1) · Lupus Erythematosus, Cutaneous (1)
Organon and Co (5) · GlaxoSmithKline (4) · Welichem Biotech Inc. (3) · Indiana University (1) · Northwestern University (1) · Peking University People's Hospital (1) · Psoriasis Treatment Center of Central New Jersey (1) · Sun Pharmaceutical Industries, Inc. (1) · University of California, San Francisco (1) · Wake Forest University Health Sciences (1)
United States (13) · Canada (7) · Japan (2) · China (1)
Victoria Butners (2) · David Rosmarin, MD (1) · Liren Tang, Ph.D (1) · Natalie Yantovskiy (1) · Paras Vakharia (1) · Raymond Cho, MD, PhD (1) · Robert Bissonnette, MD (1) · Robert Bissonnette, MD, MSc (1) · Steven R Feldman, MD, PhD (1)
PMID 37076998, PMID 37697121, PMID 38123875, PMID 40600584, PMID 34879448, PMID 38777187